GIAPREZA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug GIAPREZA contains one active pharmaceutical ingredient (API):

1	Angiotensin II UNII M089EFU921 - ANGIOTENSIN II
	Angiotensin II raises blood pressure by vasoconstriction; increased aldosterone release via direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells which stimulates Ca2+/calmodulindependent phosphorylation of myosin and causes smooth muscle contraction.
	Read more about Angiotensin II

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GIAPREZA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
GIAPREZA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01CX09		C Cardiovascular system → C01 Cardiac therapy → C01C Cardiac stimulants excl. cardiac glycosides → C01CX Other cardiac stimulants
Discover more medicines within C01CX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1800694, 1800706, 1849271
FI	Lääkealan turvallisuus- ja kehittämiskeskus	142069
FR	Base de données publique des médicaments	64441114
IT	Agenzia del Farmaco	048208019, 048208021, 048208033
LT	Valstybinė vaistų kontrolės tarnyba	1088389, 1088390, 1092290
PL	Rejestru Produktów Leczniczych	100425067
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69477001
US	FDA, National Drug Code	68547-501